Sakugawa Chihiro, Haruyama Yukihiro, Tanaka Hiroyuki, Fukushima Tsuyoshi, Kawaguchi Makiko, Kataoka Hiroaki
Section of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, Japan.
BMC Res Notes. 2017 Dec 4;10(1):674. doi: 10.1186/s13104-017-3014-x.
Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a membrane-bound serine protease inhibitor that is expressed on the surface of epithelial cells. Evidence has suggested that decreased cell surface HAI-1 in carcinoma cells results in enhanced invasiveness. However, little is known regarding the expression of HAI-1 in pancreatic ductal adenocarcinoma (PDAC). This study aimed to analyze HAI-1 expression in PDAC and its impact on patient prognosis.
HAI-1 immunohistochemistry was performed on samples from 67 PDAC cases. HAI-1 expression was increased in intraepithelial neoplasia compared to the adjacent non-neoplastic ductal epithelium. Of the 67 samples tested, 58% (39/67) of PDAC cases showed diffuse (> 75%) immunoreactivity in PDAC cells. The remaining cases showed reduced HAI-1 immunoreactivity in a substantial number of cancer cells. Although there was no correlation between HAI-1 status and tumor size, histologic grade or lymph node metastasis, diffuse HAI-1 positive cases showed longer disease-free survival (DFS; p = 0.006, log-rank test). In conclusion, HAI-1 is upregulated in pancreatic intraepithelial neoplasia and broadly expressed in PDAC cells. However, PDAC cases having areas of reduced HAI-1 immunoreactivity may show shorter DFS.
1型肝细胞生长因子激活剂抑制剂（HAI-1）是一种膜结合丝氨酸蛋白酶抑制剂，在上皮细胞表面表达。有证据表明，癌细胞表面HAI-1减少会导致侵袭性增强。然而，关于HAI-1在胰腺导管腺癌（PDAC）中的表达情况知之甚少。本研究旨在分析HAI-1在PDAC中的表达及其对患者预后的影响。
对67例PDAC病例的样本进行了HAI-1免疫组织化学检测。与相邻的非肿瘤性导管上皮相比，上皮内瘤变中HAI-1表达增加。在检测的67个样本中，58%（39/67）的PDAC病例在PDAC细胞中显示弥漫性（>75%）免疫反应性。其余病例在大量癌细胞中显示HAI-1免疫反应性降低。尽管HAI-1状态与肿瘤大小、组织学分级或淋巴结转移之间无相关性，但弥漫性HAI-1阳性病例的无病生存期（DFS）更长（p = 0.006，对数秩检验）。总之，HAI-1在胰腺上皮内瘤变中上调，并在PDAC细胞中广泛表达。然而，HAI-1免疫反应性降低区域的PDAC病例可能显示较短的DFS。
